The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Novel p53 Mutant Found in Iatrogenic Urothelial Cancers Is Dysfunctional and Can Be Rescued by a Second-site Global Suppressor Mutation
Abstract
Exposure to herbal remedies containing the carcinogen aristolochic acid (AA) has been widespread in some regions of the world. Rare A→T TP53 mutations were recently discovered in AA-associated urothelial cancers. The near absence of these mutations among all other sequenced human tumors suggests that they could be biologically silent. There are no cell banks with established lines derived from human tumors with which to explore the influence of the novel mutants on p53 function and cellular behavior. To investigate their impact, we generated isogenic mutant clones by integrase-mediated cassette exchange at the p53 locus of platform (null) murine embryonic fibroblasts and kidney epithelial cells. Common tumor mutants (R248W, R273C) were compared with the AA-associated mutants N131Y, R249W, and Q104L. Assays of cell proliferation, migration, growth in soft agar, apoptosis, senescence, and gene expression revealed contrasting outcomes on cellular behavior following introduction of N131Y or Q104L. The N131Y mutant demonstrated a phenotype akin to common tumor mutants, whereas Q104L clone behavior resembled that of cells with wild-type p53. Wild-type p53 responses were restored in double-mutant cells harboring N131Y and N239Y, a second-site rescue mutation, suggesting that pharmaceutical reactivation of p53 function in tumors expressing N131Y could have therapeutic benefit. N131Y is likely to contribute directly to tumor phenotype and is a promising candidate biomarker of AA exposure and disease. Rare mutations thus do not necessarily point to sites where amino acid exchanges are phenotypically neutral. Encounter with mutagenic insults targeting cryptic sites can reveal specific signature hotspots. Background: Biological consequences of novel signature mutations in the p53 gene of tumors from patients exposed to Aristolochia medicines are not yet known. Results: N131Y, a prominent Aristolochia -linked mutation, confers cancer-associated behavior to cells. Conclusion: Rare mutations in cancer genes can have profound consequences to protein function. Significance: N131Y is a candidate biomarker of Aristolochia -related disease and target for pharmacological rescue of p53 function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Second site suppressor mutations could help correct the conformation of mutant p53, improve the stability of p53-DNA binding, and provide a theoretical basis for the reactivation of mutant p53 (Table 4).531–545”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [535]
In the citing paper
“Second site suppressor mutations could help correct the conformation of mutant p53, improve the stability of p53-DNA binding, and provide a theoretical basis for the reactivation of mutant p53 (Table 4).531–545”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [535]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Research works printed but not linked: 29
- Oren, 2010, Mutant p53 gain-of-function in cancer, Cold Spring Harb. Perspect. Biol, 2, a001107, 10.1101/cshperspect.a001107 · DOI · Paper page
- Vogelstein, 2000, Surfing the p53 Network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
- Freed-Pastor, 2012, Mutant p53: one name, many proteins, Genes Dev, 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
- Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc. Natl. Acad. Sci. U.S.A, 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
- Petitjean, 2007, Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: Lessons from recent developments in the IARC TP53 database, Human Mutation, 28, 622, 10.1002/humu.20495 · DOI · Paper page
- Greenman, 2007, Patterns of somatic mutation in human cancer genomes, Nature, 446, 153, 10.1038/nature05610 · DOI · Paper page
- Chen, 2012, Aristolochic acid-associated urothelial cancer in Taiwan, Proc. Natl. Acad. Sci. U.S.A, 109, 8241, 10.1073/pnas.1119920109 · DOI · Paper page
- Hollstein, 2013, Analysis of TP53 mutation spectra reveals the fingerprint of the potent carcinogen, aristolochic acid, Mutat. Res, 10.1016/j.mrrev.2013.02.003 · DOI
- Olivier, 2012, Upper urinary tract urothelial cancers: where it's A:T, Nat. Rev. Cancer, 12, 503, 10.1038/nrc3311 · doi:10.1038/nrc3311
- Schetter, 2012, Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome, Proc. Natl. Acad. Sci. U.S.A, 109, 7955, 10.1073/pnas.1205457109 · DOI
- Wei, 2012, Efficient introduction of specific p53 mutations into mouse embryonic fibroblasts and embryonic stem cells, Nat. Protoc, 7, 1145, 10.1038/nprot.2012.042 · DOI
- Wei, 2011, Rapid derivation of genetically related mutants from embryonic cells harbouring a recombinase-specific Trp53 platform, Cell Cycle, 10, 1261, 10.4161/cc.10.8.15303 · doi:10.4161/cc.10.8.15303
- Mathew, 2008, Immortalized mouse epithelial cell models to study the role of apoptosis in cancer, Methods Enzymol, 446, 77, 10.1016/S0076-6879(08)01605-4 · DOI
- Whibley, 2010, Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblatsts: p53/ARF pathway disruption in spontaneous escape from senescence, J. Biol. Chem, 285, 11326, 10.1074/jbc.M109.064444 · DOI
- Joerger, 2010, The tumour suppressor p53: from structures to drug discovery, Cold Spring Harb. Perspect. Biol, 2, a000919, 10.1101/cshperspect.a000919 · DOI · Paper page
- Luo, 2001, Knock-in Hupki mice with a humanised p53 gene develop normally and show wild-type p53 responses to DNA damaging agents, Oncogene, 20, 320, 10.1038/sj.onc.1204080 · DOI
- Song, 2007, P53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nat. Cell Biol, 9, 573, 10.1038/ncb1571 · DOI · Paper page
- Baroni, 2004, A global suppressor motif for p53 cancer mutants, Proc. Natl. Acad. Sci. U.S.A, 101, 4930, 10.1073/pnas.0401162101 · DOI
- Otsuka, 2007, The screening of the second-site suppressor mutations of the common p53 mutants, Int. J. Cancer, 121, 559, 10.1002/ijc.22724 · DOI · Paper page
- Danziger, 2009, Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning, PLoS Comput. Biol, 5, e1000498, 10.1371/journal.pcbi.1000498 · DOI
- Merabet, 2010, Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for Restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights, Biochem. J, 427, 225, 10.1042/BJ20091888 · DOI
- Nedelko, 2009, TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours, Int. J. Cancer, 124, 987, 10.1002/ijc.24006 · DOI
- Liu, 2004, Human tumour p53 mutations are selected for in mouse embryonic fibroblasts harbouring a humanized p53 gene, Proc. Natl. Acad. Sci. U.S.A, 101, 2963, 10.1073/pnas.0308607101 · DOI
- Besaratinia, 2010, Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing, FASEB J, 24, 2612, 10.1096/fj.10-157263 · DOI
- Olivier, 2010, TP53 mutations in human cancers: origins, consequences, and clinical use, Cold Spring Harb. Perspect. Biol, 2, a001008, 10.1101/cshperspect.a001008 · DOI · Paper page
- Nikolova, 1998, Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability, Proc. Natl. Acad. Sci. U.S.A, 95, 14675, 10.1073/pnas.95.25.14675 · DOI · Paper page
- Joerger, 2006, Structural basis for understanding oncogenic p53 mutations and designing rescue drugs, Proc. Natl. Acad. Sci. U.S.A, 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
- Lai, 2010, Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk, J Natl. Cancer Inst, 102, 179, 10.1093/jnci/djp467 · DOI · Paper page
- Hussain, 2007, TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer, Oncogene, 26, 2166, 10.1038/sj.onc.1210279 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Metadata
- Authors
- Odell, A. F., Odell, L. R., Askham, J. M., Alogheli, H., Ponnambalam, S., & Hollstein, M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 288
- Issue
- 23
- Pages
- 16704-16714
- ISSN
- 0021-9258
- Cited by
- 11
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2659 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.